Clinical Trial Update: Evaluation of AKR1B10 as a New Marker for Interventional Therapy of Hepatocellular Carcinoma

View source ↗

Summary

A clinical trial evaluating AKR1B10 as a biomarker to guide interventional therapy for hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Snippet

Sponsor: Hebei Medical University Third Hospital | Conditions: Hepatocellular Carcinoma | Status: RECRUITING